Welcome to LookChem.com Sign In|Join Free

CAS

  • or

33621-61-3

Post Buying Request

33621-61-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1H-Benzimidazolium,6-chloro-2-[3-[5-chloro-3-ethyl-1,3-dihydro-1-(3-sulfopropyl)-6-(trifluoromethyl)-2H-benzimidazol-2-ylidene]-1-propen-1-yl]-1-ethyl-3-(3-sulfopropyl)-5-(trifluoromethyl)-,inner salt

    Cas No: 33621-61-3

  • No Data

  • No Data

  • No Data

  • Antimex Chemical Limied
  • Contact Supplier

33621-61-3 Usage

General Description

2-AMINO-5-(4-CHLOROPHENYL)-1,3,4-OXADIA& is a chemical compound that is characterized by its three-ring structure and contains an amino group and a chlorine-substituted phenyl group. It is known for its potential biological activity and is commonly used in pharmaceutical research and drug development. 2-AMINO-5-(4-CHLOROPHENYL)-1 3 4-OXADIA& has been studied for its potential anti-cancer, anti-inflammatory, and antiviral properties. Additionally, it has shown promise in the treatment of various neurological disorders. Its unique structure and versatile properties make it a valuable target for further research and exploration in the field of medicinal chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 33621-61-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,3,6,2 and 1 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 33621-61:
(7*3)+(6*3)+(5*6)+(4*2)+(3*1)+(2*6)+(1*1)=93
93 % 10 = 3
So 33621-61-3 is a valid CAS Registry Number.

33621-61-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Aldrich

  • (663387)  2-Amino-5-(4-chlorophenyl)-1,3,4-oxadiazole  95%

  • 33621-61-3

  • 663387-1G

  • 473.85CNY

  • Detail
  • Aldrich

  • (663387)  2-Amino-5-(4-chlorophenyl)-1,3,4-oxadiazole  95%

  • 33621-61-3

  • 663387-10G

  • 2,621.97CNY

  • Detail

33621-61-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-Amino-5-(4-chlorophenyl)-1,3,4-oxadiazole

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:33621-61-3 SDS

33621-61-3Relevant articles and documents

In Silico Study and In Vitro Evaluation of Novel Synthesized Quinolone Derivatives Having Five-Membered Heterocyclic Moieties

Naser, Noor H.,Raauf, Ayad M. R.,Sheehan, Mustafa R.

, p. 215 - 225 (2022/02/14)

Infectious diseases are caused by pathogens, such as viruses, bacteria, fungi, and parasites. Quinolones work by inhibition of bacterial topoisomerase IV and/or gyrase, a group of oxadiazole derivatives were incorporated into C7 piperazine ring of Gatiflo

Synthesis of indole-tethered [1,3,4]thiadiazolo and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids as anti-pancreatic cancer agents

Gummidi, Lalitha,Kerru, Nagaraju,Awolade, Paul,Raza, Asif,Sharma, Arun K.,Singh, Parvesh

, (2020/09/18)

New indole-tethered [1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one (8a-j) and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids (9a-e) were synthesized using [4+2] cycloaddition reactions of functionalized 1,3-diazabuta-1,3-dienes with indole-ketenes. All molecul

Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence in Vivo

Naclerio, George A.,Abutaleb, Nader S.,Li, Daoyi,Seleem, Mohamed N.,Sintim, Herman O.

, p. 11934 - 11944 (2020/11/26)

Clostridioides difficile is the leading cause of healthcare-associated infection in the U.S. and considered an urgent threat by the Centers for Disease Control and Prevention (CDC). Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. difficile infection (CDI), but these therapies still suffer from high treatment failure and recurrence. Therefore, new chemical entities to treat CDI are needed. Trifluoromethylthio-containing N-(1,3,4-oxadiazol-2-yl)benzamides displayed very potent activities [sub-μg/mL minimum inhibitory concentration (MIC) values] against Gram-positive bacteria. Here, we report remarkable antibacterial activity enhancement via halogen substitutions, which afforded new anti-C. difficile agents with ultrapotent activities [MICs as low as 0.003 μg/mL (0.007 μM)] that surpassed the activity of vancomycin against C. difficile clinical isolates. The most promising compound in the series, HSGN-218, is nontoxic to mammalian colon cells and is gut-restrictive. In addition, HSGN-218 protected mice from CDI recurrence. Not only does this work provide a potential clinical lead for the development of C. difficile therapeutics but also highlights dramatic drug potency enhancement via halogen substitution.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 33621-61-3